Can AI-assisted microscope facilitate breast HER2 interpretation? A multi-institutional ring study

被引:0
|
作者
Meng Yue
Jun Zhang
Xinran Wang
Kezhou Yan
Lijing Cai
Kuan Tian
Shuyao Niu
Xiao Han
Yongqiang Yu
Junzhou Huang
Dandan Han
Jianhua Yao
Yueping Liu
机构
[1] The Fourth Hospital of Hebei Medical University,Department of Pathology
[2] Nanshan District,Tencent AI Lab
来源
Virchows Archiv | 2021年 / 479卷
关键词
Artificial intelligence–assisted microscope; Breast cancer; HER2;
D O I
暂无
中图分类号
学科分类号
摘要
The level of human epidermal growth factor receptor-2 (HER2) protein and gene expression in breast cancer is an essential factor in judging the prognosis of breast cancer patients. Several investigations have shown high intraobserver and interobserver variability in the evaluation of HER2 staining by visual examination. In this study, we aim to propose an artificial intelligence (AI)–assisted microscope to improve the HER2 assessment accuracy and reliability. Our AI-assisted microscope was equipped with a conventional microscope with a cell-level classification-based HER2 scoring algorithm and an augmented reality module to enable pathologists to obtain AI results in real time. We organized a three-round ring study of 50 infiltrating duct carcinoma not otherwise specified (NOS) cases without neoadjuvant treatment, and recruited 33 pathologists from 6 hospitals. In the first ring study (RS1), the pathologists read 50 HER2 whole-slide images (WSIs) through an online system. After a 2-week washout period, they read the HER2 slides using a conventional microscope in RS2. After another 2-week washout period, the pathologists used our AI microscope for assisted interpretation in RS3. The consistency and accuracy of HER2 assessment by the AI-assisted microscope were significantly improved (p < 0.001) over those obtained using a conventional microscope and online WSI. Specifically, our AI-assisted microscope improved the precision of immunohistochemistry (IHC) 3 + and 2 + scoring while ensuring the recall of fluorescent in situ hybridization (FISH)–positive results in IHC 2 + . Also, the average acceptance rate of AI for all pathologists was 0.90, demonstrating that the pathologists agreed with most AI scoring results.
引用
收藏
页码:443 / 449
页数:6
相关论文
共 35 条
  • [31] Effectiveness of eribulin as first-line or second-line chemotherapy for HER2-negative hormone-resistant advanced or metastatic breast cancer: findings from the multi-institutional, prospective, observational KBCRN A001: E-SPEC study
    Kikawa, Yuichiro
    Kotake, Takeshi
    Tsuyuki, Shigeru
    Kang, Yookija
    Takahara, Sachiko
    Fujimoto, Yuri
    Yamashiro, Hiroyasu
    Yoshibayashi, Hiroshi
    Takada, Masahiro
    Yasuoka, Rie
    Nakatsukasa, Katsuhiko
    Yamagami, Kazuhiko
    Suwa, Hirofumi
    Okuno, Toshitaka
    Nakayama, Ichiro
    Kato, Tatsushi
    Ogura, Nobuko
    Moriguchi, Yoshio
    Ishiguro, Hiroshi
    Kagimura, Tatsuo
    Taguchi, Tetsuya
    Sugie, Tomoharu
    Toi, Masakazu
    BREAST CANCER, 2022, 29 (05) : 796 - 807
  • [32] Effectiveness of eribulin as first-line or second-line chemotherapy for HER2-negative hormone-resistant advanced or metastatic breast cancer: findings from the multi-institutional, prospective, observational KBCRN A001: E-SPEC study
    Yuichiro Kikawa
    Takeshi Kotake
    Shigeru Tsuyuki
    Yookija Kang
    Sachiko Takahara
    Yuri Fujimoto
    Hiroyasu Yamashiro
    Hiroshi Yoshibayashi
    Masahiro Takada
    Rie Yasuoka
    Katsuhiko Nakatsukasa
    Kazuhiko Yamagami
    Hirofumi Suwa
    Toshitaka Okuno
    Ichiro Nakayama
    Tatsushi Kato
    Nobuko Ogura
    Yoshio Moriguchi
    Hiroshi Ishiguro
    Tatsuo Kagimura
    Tetsuya Taguchi
    Tomoharu Sugie
    Masakazu Toi
    Breast Cancer, 2022, 29 : 796 - 807
  • [33] Natural History and Characteristics of ERBB2-mutated Hormone Receptor-positive Metastatic Breast Cancer: A Multi-institutional Retrospective Case-control Study from AACR Project GENIE
    LeNoue-Newton, Michele L.
    Chen, Sheau-Chiann
    Stricker, Thomas
    Hyman, David M.
    Blauvelt, Natalie
    Bedard, Philippe L.
    Meric-Bernstam, Funda
    Punglia, Rinaa S.
    Schrag, Deborah
    Lepisto, Eva M.
    Andre, Fabrice
    Smyth, Lillian
    Dogan, Semih
    Yu, Celeste
    Wathoo, Chetna
    Levy, Mia
    Eli, Lisa D.
    Xu, Feng
    Mann, Grace
    Lalani, Alshad S.
    Ye, Fei
    Micheel, Christine M.
    Arnedos, Monica
    CLINICAL CANCER RESEARCH, 2022, 28 (10) : 2118 - 2130
  • [34] Benefit of adjuvant chemotherapy with or without trastuzumab in pT1ab node-negative human epidermal growth factor receptor 2-positive breast carcinomas: results of a national multi-institutional study
    de Nonneville, Alexandre
    Goncalves, Anthony
    Zemmour, Christophe
    Classe, Jean M.
    Cohen, Monique
    Lambaudie, Eric
    Reyal, Fabien
    Scherer, Christophe
    Muracciole, Xavier
    Colombo, Pierre E.
    Giard, Sylvia
    Rouzier, Roman
    Villet, Richard
    Chopin, Nicolas
    Darai, Emile
    Garbay, Jean R.
    Gimbergues, Pierre
    Sabiani, Laura
    Coutant, Charles
    Sabatier, Renaud
    Bertucci, Francois
    Boher, Jean M.
    Houvenaeghel, Gilles
    BREAST CANCER RESEARCH AND TREATMENT, 2017, 162 (02) : 307 - 316
  • [35] Benefit of adjuvant chemotherapy with or without trastuzumab in pT1ab node-negative human epidermal growth factor receptor 2-positive breast carcinomas: results of a national multi-institutional study
    Alexandre de Nonneville
    Anthony Gonçalves
    Christophe Zemmour
    Jean M. Classe
    Monique Cohen
    Eric Lambaudie
    Fabien Reyal
    Christophe Scherer
    Xavier Muracciole
    Pierre E. Colombo
    Sylvia Giard
    Roman Rouzier
    Richard Villet
    Nicolas Chopin
    Emile Darai
    Jean R. Garbay
    Pierre Gimbergues
    Laura Sabiani
    Charles Coutant
    Renaud Sabatier
    François Bertucci
    Jean M. Boher
    Gilles Houvenaeghel
    Breast Cancer Research and Treatment, 2017, 162 : 307 - 316